Drug Trial Radar · NCT04929210
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
411
Actual
Start
Aug 30, 2021
Primary completion
Apr 1, 2027
Study completion Apr 13, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Conditions
- Arthritis, Psoriatic
Interventions
GuselkumabDrug
Guselkumab will be administered as subcutaneous injection.
PlaceboDrug
Matching placebo will be administered as subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 24Time frame: Baseline and Week 24
Locations
240 sites in 26 countries. Site status is shown where the registry gives one.
Arizona Arthritis and Rheumatology Research PLLC 1
Avondale, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Chandler, Arizona
Arizona Arthritis and Rheumatology Research PLLC
Mesa, Arizona
Arizona Arthritis Research, PLC.
Phoenix, Arizona
Arizona Arthritis and Rheumatology Associates
Sun City, Arizona
Southern Arizona VA Healthcare System
Tucson, Arizona
Unity Health-White County Medical Center
Searcy, Arkansas
Kaiser Permanent Medical Center
Fontana, California
Newport Huntington Medical Group
Huntington Beach, California
University Of California San Diego
La Jolla, California
Rheumatology Center of San Diego
San Diego, California
Clinical Research Center of Connecticut
Danbury, Connecticut
Bay Pines VA Healthcare System
Bay Pines, Florida
Integral Rheumatology And Immunology Specialists
Plantation, Florida
Florida Medical Clinic, P.A.
Zephyrhills, Florida
Great Lakes Clinical Trials
Chicago, Illinois
OrthoIllinois
Rockford, Illinois
Willow Rheumatology and Wellness
Willowbrook, Illinois
Johns Hopkins Bayview Medical
Baltimore, Maryland
Klein And Associates M D P A
Hagerstown, Maryland
Clinical Research Institute of Michigan, LLC
Saint Clair Shores, Michigan
St. Paul Rheumatology P A
Eagan, Minnesota
Kansas City Physician Partners
Kansas City, Missouri
Clinvest
Springfield, Missouri
STAT Research, Inc.
Vandalia, Ohio
OHSU Rheumatology Clinic, Marquam Hill
Portland, Oregon
Amarillo Center for Clinical Research
Amarillo, Texas
Austin Regional Clinic
Austin, Texas
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Adriana Pop Moody MD Clinic PA
Corpus Christi, Texas
AARA Clinical Research Lone Star Arthritis and Rheumatology 1
Fort Worth, Texas
UT Physicians Center for Autoimmunity
Houston, Texas
AARA Clinical Research Lone Star Arthritis and Rheumatology
Irving, Texas
West Texas Clinical Research
Lubbock, Texas
Southwest Rheumatology Research LLC
Mesquite, Texas
Epic Medical Research
Red Oak, Texas
DM Clinical Research
Tomball, Texas
Swedish Medical Center
Seattle, Washington
Cosultorios Reumatologógicos Pampa
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Showing 40 of 240 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.